Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totaling 316,118 shares, a decline of 34.7% from the March 15th total of 484,373 shares. Based on an average trading volume of 118,913 shares, the days-to-cover ratio is presently 2.7 days. Approximately 3.1% of the company’s shares are sold short.

Vivos Therapeutics Trading Up 10.7%

Shares of NASDAQ:VVOS traded up $0.13 during trading on Tuesday, reaching $1.35. 160,818 shares of the company were exchanged, compared to its average volume of 169,101. The firm has a market capitalization of $14.13 million, a PE ratio of -0.76 and a beta of 6.93. The business’s fifty day simple moving average is $1.38 and its 200-day simple moving average is $2.02. Vivos Therapeutics has a 12-month low of $1.09 and a 12-month high of $7.95. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.78 and a quick ratio of 0.78.

Insider Buying and Selling

In other Vivos Therapeutics news, major shareholder Michael C. Skaff bought 1,353,625 shares of Vivos Therapeutics stock in a transaction on Tuesday, March 31st. The shares were acquired at an average price of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the purchase, the insider directly owned 1,353,625 shares in the company, valued at approximately $1,813,857.50. This trade represents a ? increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in Vivos Therapeutics during the 2nd quarter valued at $65,000. B. Riley Wealth Advisors Inc. purchased a new stake in shares of Vivos Therapeutics in the 2nd quarter worth $220,000. Connective Capital Management LLC bought a new position in shares of Vivos Therapeutics during the 3rd quarter worth $620,000. Acorn Wealth Advisors LLC bought a new position in shares of Vivos Therapeutics during the 4th quarter worth $30,000. Finally, DRW Securities LLC increased its stake in shares of Vivos Therapeutics by 179.5% during the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares during the period. 26.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $4.92.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.